EOS Technology Investment Syndicate

Novosound is the first spin-out company to emerge from the University of the West of Scotland. Novosound specializes in the design and manufacturing of innovative NDT products using groundbreaking, thin-film manufacturing techniques which addresses the limitations of traditional ultrasound. Novosound design and end-to-end manufacturing capabilities enables the development of highly customizable and scalable ultrasound solutions

ENOUGH, formerly known as 3fbio Ltd., is a technology spin-out from the University of Strathclyde, established to develop and commercialize innovative patented technology for the production of mycoprotein, a meat-free food product. The company employs integrated fermentation processes that combine the production of mycoprotein with existing bio-refinery operations, which also generate bioethanol and animal feed as co-products. By utilizing glucose syrup as feedstock for mycoprotein and carbohydrate feedstock for bioethanol, ENOUGH aims to enhance production economics while promoting sustainable food solutions. Incorporated in 2015 and based in Glasgow, United Kingdom, the company focuses on transforming the food, fuel, and feed sectors through its advanced production methods.

ENOUGH, formerly known as 3fbio Ltd., is a technology spin-out from the University of Strathclyde, established to develop and commercialize innovative patented technology for the production of mycoprotein, a meat-free food product. The company employs integrated fermentation processes that combine the production of mycoprotein with existing bio-refinery operations, which also generate bioethanol and animal feed as co-products. By utilizing glucose syrup as feedstock for mycoprotein and carbohydrate feedstock for bioethanol, ENOUGH aims to enhance production economics while promoting sustainable food solutions. Incorporated in 2015 and based in Glasgow, United Kingdom, the company focuses on transforming the food, fuel, and feed sectors through its advanced production methods.

Alfacyte Ltd. develops an immunoregulatory formulation for the oral treatment of food allergies based on the immunological activities of two candidate cytokines, with adjuvant-like activities. Its immunoregulatory combination therapy is used for the oral treatment of peanut allergy.